Morning Briefing
Summaries of health policy coverage from major news organizations
Seeking Fresh Start From Its Troubles, Cassava Changes Its Name To Filana
Cassava Sciences has rebranded as Filana Therapeutics, shedding the baggage associated with the old name as the biotech plants itself in a new therapeutic area. As Cassava, the biotech mounted a failed attempt to show that its simufilam could improve outcomes in Alzheimer’s disease. By the time the phase 3 data sank the Alzheimer’s program last spring, Cassava was facing a Department of Justice (DOJ) investigation and class-action litigation tied to alleged scientific misconduct and misleading statements. The company recently reached settlements in the DOJ case and class-action lawsuit. (Taylor, 3/10)
On weight loss drugs —
Novo Nordisk received a warning from the Food and Drug Administration for failing to report suspected incidents of side effects caused by its medicines, a step that is required by federal law. (Silverman, 3/10)
The obesity drug semaglutide (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed. (Bankhead, 3/10)
Hims & Hers Health Inc. has hired Kathryn Beiser, who led communications at Eli Lilly & Co. for five years, as the telehealth company charts a new era selling brand-name obesity drugs. Beiser, a public relations veteran who’s held senior positions at a number of companies including Kaiser Permanente, resigned from Lilly last year. She officially joined Hims last month as chief communications officer and reports to Chief Executive Officer Andrew Dudum. (Muller, 3/10)
In other pharmaceutical news —
Medtronic has signed a definitive agreement to acquire neurovascular medtech company Scientia Vascular for $550 million. The deal is expected to close in the first half of Medtronic’s fiscal 2027, which starts in April. It is subject to regulatory approvals and closing conditions. (Dubinsky, 3/10)
Monday, the Australian biopharma broke ground on an expansion at its Kankakee, Illinois, facility, a move set to substantially bolster CSL’s production capacity for plasma-derived therapy. (Kansteiner, 3/10)
Four Illinois mothers would never have allowed their prematurely born babies to be fed a specialized formula made by Abbott Laboratories had they known about the risks, an attorney for the parents argued in court Monday, while a lawyer for the company countered that the formula is not dangerous and that additional warnings about it would not have prevented the infants from getting sick. (Schencker, 3/10)
AbbVie’s CEO Robert Michael is emerging from his sophomore year at the helm with $32.5 million in 2025 compensation, marking a hefty 75% spike from his first-year pay and solidifying the rising chief as one of the highest-paid executives in the biopharma industry. (Becker, 3/10)
